Free Trial

Emergent Biosolutions (EBS) Competitors

Emergent Biosolutions logo
$7.33 0.00 (0.00%)
Closing price 03:59 PM Eastern
Extended Trading
$7.38 +0.05 (+0.68%)
As of 07:01 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

EBS vs. JNJ, CLDX, DVAX, INVA, MNKD, NVAX, OPK, GERN, RGLS, and MYGN

Should you be buying Emergent Biosolutions stock or one of its competitors? The main competitors of Emergent Biosolutions include Johnson & Johnson (JNJ), Celldex Therapeutics (CLDX), Dynavax Technologies (DVAX), Innoviva (INVA), MannKind (MNKD), Novavax (NVAX), OPKO Health (OPK), Geron (GERN), Regulus Therapeutics (RGLS), and Myriad Genetics (MYGN). These companies are all part of the "medical" sector.

Emergent Biosolutions vs. Its Competitors

Johnson & Johnson (NYSE:JNJ) and Emergent Biosolutions (NYSE:EBS) are both medical companies, but which is the superior business? We will contrast the two businesses based on the strength of their profitability, valuation, analyst recommendations, earnings, institutional ownership, risk, dividends and media sentiment.

Johnson & Johnson has a net margin of 24.42% compared to Emergent Biosolutions' net margin of -13.63%. Johnson & Johnson's return on equity of 33.46% beat Emergent Biosolutions' return on equity.

Company Net Margins Return on Equity Return on Assets
Johnson & Johnson24.42% 33.46% 13.30%
Emergent Biosolutions -13.63%-0.52%-0.17%

Johnson & Johnson presently has a consensus price target of $171.00, suggesting a potential upside of 8.42%. Emergent Biosolutions has a consensus price target of $14.33, suggesting a potential upside of 95.54%. Given Emergent Biosolutions' stronger consensus rating and higher probable upside, analysts clearly believe Emergent Biosolutions is more favorable than Johnson & Johnson.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Johnson & Johnson
0 Sell rating(s)
11 Hold rating(s)
7 Buy rating(s)
2 Strong Buy rating(s)
2.55
Emergent Biosolutions
0 Sell rating(s)
0 Hold rating(s)
3 Buy rating(s)
0 Strong Buy rating(s)
3.00

69.6% of Johnson & Johnson shares are held by institutional investors. Comparatively, 78.4% of Emergent Biosolutions shares are held by institutional investors. 0.2% of Johnson & Johnson shares are held by company insiders. Comparatively, 1.2% of Emergent Biosolutions shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.

Johnson & Johnson has a beta of 0.41, indicating that its stock price is 59% less volatile than the S&P 500. Comparatively, Emergent Biosolutions has a beta of 2.09, indicating that its stock price is 109% more volatile than the S&P 500.

Johnson & Johnson has higher revenue and earnings than Emergent Biosolutions. Emergent Biosolutions is trading at a lower price-to-earnings ratio than Johnson & Johnson, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Johnson & Johnson$88.82B4.27$14.07B$8.9917.54
Emergent Biosolutions$1.04B0.38-$190.60M-$2.71-2.70

In the previous week, Johnson & Johnson had 108 more articles in the media than Emergent Biosolutions. MarketBeat recorded 114 mentions for Johnson & Johnson and 6 mentions for Emergent Biosolutions. Johnson & Johnson's average media sentiment score of 1.37 beat Emergent Biosolutions' score of 0.78 indicating that Johnson & Johnson is being referred to more favorably in the media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Johnson & Johnson
97 Very Positive mention(s)
4 Positive mention(s)
8 Neutral mention(s)
3 Negative mention(s)
1 Very Negative mention(s)
Positive
Emergent Biosolutions
3 Very Positive mention(s)
0 Positive mention(s)
3 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive

Summary

Johnson & Johnson beats Emergent Biosolutions on 12 of the 17 factors compared between the two stocks.

Get Emergent Biosolutions News Delivered to You Automatically

Sign up to receive the latest news and ratings for EBS and its competitors with MarketBeat's FREE daily newsletter.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding EBS and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NYSE and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

EBS vs. The Competition

MetricEmergent BiosolutionsMED IndustryMedical SectorNYSE Exchange
Market Cap$397.86M$2.96B$5.56B$20.59B
Dividend YieldN/A2.42%5.25%3.73%
P/E Ratio-2.708.0519.5826.08
Price / Sales0.38296.11442.2743.16
Price / Cash3.8242.7337.5022.41
Price / Book0.827.748.084.61
Net Income-$190.60M-$54.96M$3.16B$982.91M
7 Day Performance4.86%6.04%3.77%3.26%
1 Month Performance8.83%4.47%3.90%4.37%
1 Year Performance-21.10%6.12%34.22%14.95%

Emergent Biosolutions Competitors List

CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
EBS
Emergent Biosolutions
4.3941 of 5 stars
$7.33
flat
$14.33
+95.5%
-16.6%$397.86M$1.04B-2.702,420News Coverage
JNJ
Johnson & Johnson
4.8738 of 5 stars
$155.23
-0.5%
$170.88
+10.1%
+6.1%$373.49B$88.82B17.27138,100Trending News
Upcoming Earnings
Analyst Forecast
CLDX
Celldex Therapeutics
3.0904 of 5 stars
$20.98
-4.6%
$50.11
+138.9%
-39.6%$1.39B$7.56M-7.77150Positive News
DVAX
Dynavax Technologies
4.3803 of 5 stars
$10.30
+0.3%
$24.00
+133.0%
-1.5%$1.24B$277.25M-19.81350
INVA
Innoviva
4.3115 of 5 stars
$18.91
-1.6%
$55.00
+190.9%
+15.5%$1.19B$369.84M-18.72100Positive News
MNKD
MannKind
2.5436 of 5 stars
$3.54
-1.7%
$10.33
+191.9%
-28.6%$1.08B$285.50M35.40400
NVAX
Novavax
4.4934 of 5 stars
$6.61
-2.8%
$17.00
+157.2%
-40.5%$1.07B$682.16M2.491,990
OPK
OPKO Health
4.6579 of 5 stars
$1.34
-1.5%
$2.75
+105.2%
+7.0%$1.06B$713.10M-19.142,997News Coverage
Positive News
Analyst Upgrade
GERN
Geron
3.3134 of 5 stars
$1.37
-4.2%
$5.06
+269.5%
-68.6%$872.58M$76.99M-6.5270News Coverage
Analyst Forecast
RGLS
Regulus Therapeutics
1.5997 of 5 stars
$8.16
flat
$8.50
+4.2%
N/A$564.92MN/A-11.1830
MYGN
Myriad Genetics
4.4646 of 5 stars
$5.29
-5.5%
$14.38
+171.9%
-77.3%$487.63M$837.60M-4.722,700News Coverage

Related Companies and Tools


This page (NYSE:EBS) was last updated on 7/10/2025 by MarketBeat.com Staff
From Our Partners